C4 Therapeutics Inc
NASDAQ:CCCC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
US |
|
L
|
Littelfuse Inc
XBER:LFS
|
US |
C4 Therapeutics Inc
C4 Therapeutics is a drug-development company focused on targeted protein degradation. Instead of trying to block a disease-causing protein, it designs small-molecule medicines that tag that protein for removal by the cell’s own cleanup system. Its main work is in oncology, where it builds drug candidates aimed at cancers driven by hard-to-treat proteins. The company makes money in two main ways: by collaborating with larger pharmaceutical partners and by developing its own drug pipeline. In partnerships, it can receive research funding, milestone payments, and royalties if a partnered drug reaches the market. If its own programs succeed, it could also earn future product sales or licensing income, though that depends on clinical and regulatory progress. What makes C4 different is its focus on degradation rather than simple inhibition. That approach is meant to address proteins that are difficult to drug with standard medicines, giving the company a distinct role in the biotech value chain as a designer of early-stage precision medicines rather than a traditional drug seller.
C4 Therapeutics is a drug-development company focused on targeted protein degradation. Instead of trying to block a disease-causing protein, it designs small-molecule medicines that tag that protein for removal by the cell’s own cleanup system. Its main work is in oncology, where it builds drug candidates aimed at cancers driven by hard-to-treat proteins.
The company makes money in two main ways: by collaborating with larger pharmaceutical partners and by developing its own drug pipeline. In partnerships, it can receive research funding, milestone payments, and royalties if a partnered drug reaches the market. If its own programs succeed, it could also earn future product sales or licensing income, though that depends on clinical and regulatory progress.
What makes C4 different is its focus on degradation rather than simple inhibition. That approach is meant to address proteins that are difficult to drug with standard medicines, giving the company a distinct role in the biotech value chain as a designer of early-stage precision medicines rather than a traditional drug seller.
